Martin Haluzı́k

Research interests

Publications

• IFSO Worldwide Survey 2020–2021: Current Trends for Bariatric and Metabolic Procedures

  Obesity Surgery · 2024 · 10.1007/s11695-024-07118-3

• Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review

  Advances in Therapy · 2022 · 10.1007/s12325-022-02153-x

• European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity

  European Journal of Endocrinology · 2020 · 10.1530/eje-19-0893

• PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

  Diabetes Care · 2019 · 10.2337/dc19-0749

• PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

  Diabetes Care · 2019 · 10.2337/dc19-0749

• Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

  The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)32261-x

• The role of adipose tissue immune cells in obesity and low-grade inflammation

  Journal of Endocrinology · 2014 · https://doi.org/10.1530/joe-14-0283

• Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet

  European Journal of Endocrinology · 2009 · 10.1530/eje-09-0417

• The role of resistin as a regulator of inflammation: Implications for various human pathologies

  Clinical Immunology · 2009 · 10.1016/j.clim.2009.07.013

• Plasma Concentrations of Fibroblast Growth Factors 19 and 21 in Patients with Anorexia Nervosa

  The Journal of Clinical Endocrinology & Metabolism · 2008 · https://doi.org/10.1210/jc.2008-0746

• Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity

  Clinical Endocrinology · 2008 · 10.1111/j.1365-2265.2008.03502.x

• Increased Subcutaneous and Epicardial Adipose Tissue Production of Proinflammatory Cytokines in Cardiac Surgery Patients: Possible Role in Postoperative Insulin Resistance

  The Journal of Clinical Endocrinology & Metabolism · 2006 · 10.1210/jc.2006-1044

• Multicentric, Randomized, Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm Versus Routine Glucose Management Protocols in Intensive Care Unit Patients

  Diabetes Care · 2006 · 10.2337/diacare.29.02.06.dc05-1689

• Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum

  Annals of the Rheumatic Diseases · 2006 · https://doi.org/10.1136/ard.2006.054734

• Adipocytokines and cancer

  Physiological Research · 2006 · 10.33549/physiolres.930848

• Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B–null mice

  Journal of Clinical Investigation · 2006 · 10.1172/jci24867

• Serum Adiponectin and Resistin Concentrations in Patients with Restrictive and Binge/Purge Form of Anorexia Nervosa and Bulimia Nervosa

  The Journal of Clinical Endocrinology & Metabolism · 2005 · https://doi.org/10.1210/jc.2004-1364

• Genetic Background (C57BL/6J Versus FVB/N) Strongly Influences the Severity of Diabetes and Insulin Resistance in ob/ob Mice

  Endocrinology · 2004 · 10.1210/en.2004-0219

• Adiponectin and its role in the obesity-induced insulin resistance and related complications.

  Physiological Research · 2004 · 10.33549/physiolres.930479

• Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1–deficient mice

  Journal of Clinical Investigation · 2004 · 10.1172/jci17763

• Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1–deficient mice

  Journal of Clinical Investigation · 2004 · 10.1172/jci200417763

• Peroxisome Proliferator–Activated Receptor-α Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis

  Diabetes · 2003 · 10.2337/diabetes.52.7.1770

• Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass

  Journal of Biological Chemistry · 2003 · https://doi.org/10.1074/jbc.m300043200

• Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

  Journal of Clinical Investigation · 2003 · https://doi.org/10.1172/jci200317223

• Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes

  Journal of Clinical Investigation · 2003 · https://doi.org/10.1172/jci17223

• Enhanced insulin sensitivity in mice lacking ganglioside GM3

  Proceedings of the National Academy of Sciences · 2003 · https://doi.org/10.1073/pnas.0635898100

• WY14,643, a Peroxisome Proliferator-activated Receptor α (PPARα) Agonist, Improves Hepatic and Muscle Steatosis and Reverses Insulin Resistance in Lipoatrophic A-ZIP/F-1 Mice

  Journal of Biological Chemistry · 2002 · 10.1074/jbc.m202449200

Current projects

No projects listed.